Study of 18F-0502B PET Imaging Targeting α-synuclein in the Diagnosis of α-synuclein-related Dise… (NCT05757804) | Clinical Trial Compass
UnknownNot Applicable
Study of 18F-0502B PET Imaging Targeting α-synuclein in the Diagnosis of α-synuclein-related Diseases
China20 participantsStarted 2023-03-17
Plain-language summary
To explore the diagnostic value of 18F-0502B brain imaging for α-Syn protein-related diseases in patients with PD. To evaluate the imaging range of α-Syn protein density in patients with α-Syn protein-related diseases and to assess the level of abnormal α-Syn protein deposition by PET imaging with this PET tracer, and its safety in human studies.
Who can participate
Age range60 Years – 80 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Age between 60 and 80 years; gender is not limited.
✓. Normal motor function as determined by the investigator through testing; UPDRS score of 0.
✓. No neurological disease, major chronic disease, malignancy or acute infectious disease as confirmed by the investigator.
✓. Informed consent must be signed in writing by the subject or his/her legal guardian or caregiver.
✓. Blood count: white blood cell count (WBC) 4-10×109/L; platelets (PLT) 100-300×109/L; hemoglobin (HB) 120-160 g/L; renal function: serum creatinine less than or equal to the upper limit of the normal range; liver function: bilirubin, AST (SGOT)/ALT (SGPT) less than or equal to the upper limit of the normal range. Electrocardiogram: no significant abnormalities.
✓. No neurological disorders, major chronic diseases, malignant tumors or acute infectious diseases as confirmed by the investigator, no family history of neurodegenerative movement disorders, no family history of neurological disorders related to movement disorders.
✓. Be willing and able to cooperate with all the projects of this study.
✓. Age between 60 and 80 years old; gender is not limited.
Exclusion criteria
✕. Suffering from other serious neurological diseases, or gastrointestinal, cardiovascular, liver, kidney, blood system, tumor endocrine, respiratory system, immune deficiency and other serious diseases.
✕. In the past year, in addition to participating in the expected radiation exposure of this clinical study, have participated in other research programs or clinical care, resulting in radiation exposure exceeding the effective dose of 50 mSv.